Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways.
ACS medicinal chemistry letters June 12, 2025 DOI: 10.1021/acsmedchemlett.5c00263
Summary
Imagine treatments for brain and body disorders that work without psychedelic side effects. Researchers designed non-hallucinogenic compounds, finding they offer optimized receptor selectivity, metabolic synergy, and neuroplastic potential. This novel chemical framework shows therapeutic promise for complex metabolic and neuropsychiatric conditions.
Abstract
Substituted tryptamines with selective 5-HT2A/2C activity demonstrate therapeutic promise without psychedelic effects. Two recent patent applications describe nonhallucinogenic analogs for metabolic and neuropsychiatric disorders. These agents exhibit optimized receptor selectivity, metabolic synergy, and neuroplastic potential, offering a novel chemical framework for multimodal treatment strategies.